Syndax Pharmaceuticals
Clinical trials sponsored by Syndax Pharmaceuticals, explained in plain language.
A biopharmaceutical company developing cancer therapies, including treatments for leukemia and other malignancies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise in slowing lung scarring Results expected Sep 2026 (estimated) May already have reported ↗
- New hope for Hard-to-Treat leukemia: targeted pill combined with chemotherapy enters human trials Results expected Feb 2027 (estimated) May already have reported ↗